European governments must ensure R&D is converted into new businesses, new products

National governments in Europe need to do more to ensure that R&D innovation in the biotech industry is translated into new businesses, new products and additional jobs according to a new report from Ernst & Young and biotech trade group EuropaBio, titled What Europe has to offer biotechnology companies: unraveling the tax, financial and regulatory framework.

The report found significant variation in the regulatory and policy environment for biotechnology companies across Europe, which has a significant impact on success and policies across the region. The differences range from basic policies and regulations which encourage financing for start-ups, to the ability to encourage entrepreneurs and attract competent managers.